info@seagull-health.com
SeagullHealth
search
Nivolumab and Relatlimab(Opdualag)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Opdualag(Nivolumab and Relatlimab) Instructions:Uses,Dosage, Side Effects
OPDUALAG is a fixed-dose combination biologic therapy for intravenous use, comprising two distinct monoclonal antibodies: nivolumab, which targets the PD-1 receptor, and relatlimab, which targets the LAG-3 receptor. This dual-immunotherapy approach is designed to enhance T-cell-mediated anti-tumor immune responses. The product is supplied as a sterile, preservative-free solution in a single-dose vial and must be stored refrigerated. It is manufactured by Bristol-Myers Squibb and is indicated specifically for a defined patient population with advanced melanoma.
OPDUALAG is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable oOPDUALAG is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. The safety and efficacy in pediatric patients under 12 years of age, or those 12 years and older weighing less than 40 kg, have not been established.r metastatic melanoma. The safety and efficacy in pediatric patients under 12 years of age, or those 12 years and older weighing less than 40 kg, have not been established.
480 mg nivolumab and 160 mg relatlimab administered via intravenous infusion every 4 weeks.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
